Recombinant mammalian cell-derived somatropin: A review of its pharmacological properties and therapeutic potential in the management of wasting associated with HIV infection

BioDrugs

Volumn 8, Issue 5, 1997, Pages 394-414

  Perry, Caroline M ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; RECOMBINANT MAMMALIAN CELL DERIVED SOMATROPIN; UNCLASSIFIED DRUG;

ARTHRALGIA; BODY FAT; BODY WEIGHT; COST CONTROL; DIARRHEA; DRUG TOLERABILITY; HEALTH CARE COST; HOME CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEAN BODY WEIGHT; LIPID OXIDATION; MUSCLE ATROPHY; MYALGIA; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN SYNTHESIS; QUALITY OF LIFE; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TREADMILL EXERCISE; VIRUS REPLICATION;

EID: 0030725573     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199708050-00007     Document Type: Review

References (84)

1. Carter MJ, Facklam TJ, Long PC, et al. Are continuous cell lines safe as substrates for human drugs and biologies? A case study with human growth hormone. Dev Biol Stand 1989; 70: 101-7
2. Chlebowski RT, Grosvenor MB, Bernhard NH, et al. Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS. Am J Gastroenterol 1989; 84 (10): 1288-93
3. Kotler DP, Tierney AR, Wang J, et al. Magnitude of body-cell-mass depletion and the timing of death from wasting AIDS. Am J Clin Nutr 1989; 50: 444-7
4. Grunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 1992; 327 (5): 329-37
5. Kotler DP, Wang J, Pierson RN. Body composition studies in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr 1985; 42: 1255-65
6. Grunield C. What causes wasting in AIDS? N Engl J Med 1995 Jul 13; 333: 123-4
7. Chan ISF, Neaton JD, Saravolatz LD, et al. Frequencies of opportunistic diseases prior to death among HIV-infected persons. Community Programs for Clinical Research on AIDS. AIDS 1995 Oct; 9: 1145-51
8. Centers for Disease Control and Prevention. HIV/AIDS surveillance report, 1996 [Accessed 1997 Sep 1] Available from: URL:http://www.cdc.gov/nchstp/hivaids/stats/hasrlink.htm. 1997; 8 (2 [online])
9. Center for Disease Control. Revision of the CDC surveillance case definition of AIDS. MMWR Morb Mortal Wkly Rep 1987: 3015
10. Gazard BG. Review article: treatment of the gastrointestinal manifestations of AIDS. Aliment Pharmacol Ther 1990 Aug; 4: 317-24
11. Hellerstein MK, Kahn J, Mudie H, et al. Current approach to the treatment of human immunodeficiency virus-associated weight loss: pathophysiologic considerations and emerging management strategies. Semin Oncol 1990; 17 Suppl. 9 (6): 17-33
12. Mulligan K, Tai V, Schambelan M. Cross-sectional and longitudinal evaluation of body composition in men with HIV infection. J Acquir Immune Defic Syndrom Hum Retrovirol 1997; 15 (1): 43-8
13. Kotler DP. Therapeutic options in AIDS wasting. In: Wasting und AIDS. Stuttgart: Georg Thieme Verlag, 1997: 63-70
14. 2-microglobulin and other early predictors of human immunodeficiency virus type 1-related wasting. Ann Epidemiol 1994 Jan; 4: 32-9
15. Macallan DC, Noble C, Baldwin C, et al. Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med 1995; 333 (2): 83-8
16. Graham NMH, Muñoz A, Bacellar H, et al. Clinical factors associated with weight loss related to infection with human immunodeficiency virus type 1 in the Multicentre AIDS Cobort Study. Am J Epidemiol 1993; 137 (4): 439-46
17. Coodley GO, Loveless MO, Merrill TM. The HIV wasting syndrome: a review. J Acquir Immune Defic Syndr 1994; 7 (7): 681-94
18. Dworkin BM, Wormser GP, Axelrod F, et al. Dietary intake in patients with acquired immunodeficiency syndrome (AIDS), patients with AIDS-related complex, and serologically positive human immunodeficiency virus patients:correlations with nutritional status. J Parent Enter Nutr 1990; 14 (6): 605-9
19. Mulligan K, Grunfeld C. Nutrition in HIV infection. Curr Opin Gastroenterol 1994; 10: 218-26
20. Muurahainen N, Mazzoni C, Rider L, et al. Trends in weight and body cell mass (BCM) changes in HIV-infected men [abstract]. Nutrition 1997; 13: 32
21. Teixeira A, Leu JC, Honderlick P, et al. Variation in body weight and plasma viral load in HIV patients treated with tritherapy including a protease inhibitor [abstract]. Nutrition 1997; 13: 1-10
22. Berger D, Bucher G, Cinoch P, et al. Measurement of body weight and body cell mass in patients receiving highly active antiretroviral therapy (HAART). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1997 Sep 28-Oct 1; Toronto, 247
23. Hommes MJT, Romijn JA, Godfried MH, et al. Increased resting energy expenditure in human immunodeficiency virus-infected men. Metabolism 1990 Nov; 39 (11): 1186-90
24. Kotler DP, Tierney AR, Culpepper-Morgan JA, et al. Effect of home total parenteral nutrition on body composition in patients with acquired immunodeficiency syndrome. J Parent Enter Nutr 1990; 14: 454-8
25. Chlebowski RT. Significance of altered nutritional status in Acquired Immune Deficiency Syndrome (AIDS). Nutr Cancer 1985; 7 (1&2): 85-91
26. Macallan DC, Noble C, Baldwin C, et al. Prospective analysis of patterns of weight change in stage IV human immunodeficiency virus infection. Am J Clin Nutr 1993; 58: 417-24
27. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting: a randomized, placebo-controlled trial. Ann Intern Med 1996 Dec 1; 125: 873-82
28. Palenicek JP, Graham NMH, He YD, et al. Weight loss prior to clinical AIDS as a predictor of survival. J Acquir Immune Defic Syndr 1995; 10 (3): 366-73
29. Wheeler DA, Muurahainen N, Elion R, et al. Change in body weight (wt) as a predictor of death and opportunistic complications (OC) in HIV by history of prior OC [abstract]. 11th International Conference on AIDS. 1996 Jul 7-12; Vancouver
30. Süttmann U, Ockenga J, Selberg O, et al. Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients. J Acquir Immune Defic Syndr 1995; 8: 239-46
31. Cahill GFJ. Starvation in man. N Engl J Med 1970; 282: 668-75
32. Brennan MF. Uncomplicated starvation versus cancer cachexia. Cancer Res 1977; 37: 2359-64
33. Laurence J. Growth hormone in HIV/AIDS: current uses and future prospects. Pediat AIDS HIV Infect 1995 Oct; 6: 281-91
34. Manson JM, Smith RJ, Wilmore DW. Growth hormone stimulates protein synthesis during hypocaloric parenteral nutrition. Role of hormonal-substrate environment. Ann Surg 1988 (208): 136-42
35. Ward HC, Halliday D, Sim AJ. Protein and energy metabolism with biosynthetic human growth hormone after gastrointestinal surgery. Ann Surg 1987; 206: 56-61
36. Gore DC, Honeycutt D, Jahoor F, et al. Effect of exogenous growth hormone on whole-body and isolated-limb protein kinetics in burned patients. Arch Surg 1991; 126: 38-43
37. Byrne TA, Motissey TB, Gatzen C, et al. Anabolic therapy with growth hormone accelarates protein gain in surgical patients requiring nutritional rehabilitation. Ann Surg 1993; 218: 400-18
38. Jeevanandam M, Ali MR, Holaday NJ, et al. Adjuvant recombinant human growth hormone normalies plasma amino acids in parenterally fed trauma patients. J Parent Enter Nutr 1995 Mar-Apr; 19: 137-44
39. Petersen SR, Holaday NJ, Jeevanandam M, et al. Enhancement of protein synthesis efficiency in parenterally fed trauma victims by adjuvant recombinant human growth hormone. J Trauma 1994 May; 36: 726-33
40. Serono Laboratories Inc. Serostim™ Product Monograph. Randolph (MA). USA, July 1996
41. Leung DW, Spencer SA, Cachinaes G, et al. Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature 1987; 330: 537-43
42. Henneman PH. The effect of human growth hormone on growth of patients with hypopituitarism. A combined study. JAMA 1968 Sept 16; 205 (12): 828-36
43. Rappaport R, Mugnier E, Limoni C, et al. A 5-year prospective study of growth hormone (GH)-deficient children treated with GH before the age of 3 years. J Clin Endocrinol Metab 1997; 82 (2): 452-6
44. Frasier SD, Rudlin CR, Zeisel HJ, et al. Effect of somatotropin of mammalian cell origin in growth hormone deficiency. Am J Dis Child 1992; 146 (5): 582-7
45. Mulligan K, Grunfeld C, Hellerstein MK, et al. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1993 Oct; 77: 956-62
46. Mulligan K, Tai V, Schambelan M. The effects of chronic growth hormone therapy on energy metabolism in patients with HIV-associated weight loss (abstract). 10th International Congress of Endocrinology. 1996 Jun 12-15; San Francisco, 72
47. Lieberman SA, Butterfield GE, Harrison D, et al. Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1994 Feb; 78: 404-10
48. Paton N. Short-term growth hormone treatment for wasting associated with acute opportunistic infections [abstract]. Second International Conference on Nutrition and HIV infection. 1997 Apr 23-25; Cannes
49. Gelato MC, Frost RA, DeCristofaro K, et al. Growth hormone (GH) deficiency and diminished anabolic response in muscle of HIV infected adults [abstract]. 10th International Congress of Endocrinology. 1996 Jun 12-15; San Francisco, 253
50. Laurence J, Grimison B, Gonenne A. Effect of recombinant human growth hormone on acute and chronic human immunodeficiency virus infection in vitro. Blood 1992 Jan 15; 79: 467-72
51. Serono Laboratories Inc. Somatropin prescribing information. Randolph (MA), USA, 1996
52. Denny TN, Landy H, Breitmeyer JB. Immunomodulatory effects of mammalian cell-derived human recombinant growth hormone in patients with AIDS wasting [abstract]. 3rd Conference on Retroviruses and Opportunistic Infections. 1996 Jan 28-Feb 1; Washington, DC, 112
53. Murphy WJ, Tsarfaty G, Longo DL. Growth hormone exerts hematopoietic growth-promoting effects in vivo and partially counteracts the myelosuppressive effects of azidothymidine. Blood 1992 Sep 15; 80: 1443-7
54. Hirschfeld S. Use of human recombinant growth hormone and human recombinant insulin-like growth factor-1 in patients with human immunodeficiency virus infection. Horm Res 1996; 46 (4-5): 215-21
55. Zeisel HJ, Petrykowski V, Wais U. Pharmacokinetics and short-term metabolic effects of mammalian cell-derived biosynthetic human growth hormone in man. Horm Res 1992; 37 Suppl. 2: 5-13
56. Griffin GE. Serostim: Recombinant Human Growth Hormone, mammalian-cell derived (somatropin) in the treatment of HIV-associated wasting/weight loss. The Ares-Serono Group, Geneva, Switzerland, 1996 (Data on file)
57. Ares-Serono Group, Geneva, Switzerland. Recombinant - human growth hormone (Saizen®) pharmacokinetic study after IV IM and SC administration to 12 healthy volunteers down-regulated with somatostatin (Stilamin®) IV infusion. 1993 (Data on file)
58. Ares-Serono Group, Geneva, Switzerland. Pharmacokinetic and pharmacodynamic technical report of study GF 7021. 1996 (Data on file)
59. Berger DS, LaMarca A, Landy H, et al. A phase III study of recombinant human growth hormone (mammalian cell-derived) in patients with AIDS wasting [abstract]. 11th International Conference on AIDS. 1996 Jul 7-12; 1: 26
60. Serono Laboratories Inc., Norwell, MA, USA. Treatment of AIDS-associated catabolism/weight loss. (9037) 1996 (Data on file)
61. Klauke S, Fruehauf L, Michels B, et al. Use of bioelectrical impedance analysis to determine changes in body composition in patients with HIV-associated wasting [abstract]. Second International Conference on Nutrition and HIV Infection. 1997 Apr 23-25; Cannes, 285
62. Bozzette SA, Hays RD, Berry SH, et al. A Perceived Health Index for use in persons with advanced HIV disease: derivation, reliability, and validity. Med Care 1994 (32): 716-31
63. Tai VW, Mulligan K, Culp J, et al. The effects of chronic growth hormone therapy on dietary intake in patients with HIV-associated weight loss [abstract], 11th International Conference on AIDS. 1996 Jul 7-12; 1: 122
64. Nemechek PM, Sackuvich L, Zakovich P, et al. Maintenance of body cell mass and phase angle after discontinuation of human growth hormone (r-hGH; Serostim) [abstract]. Second International Conference on Nutrition and HIV Infection. 1997 Apr 23-25; Cannes
65. Klauke S, Frühauf L, Michels B, et al. HIV-associated wasting syndrome - therapy with mammalian cell-derived recombinant human growth hormone (r-hGH) [abstract], 11th International Conference on AIDS; 1996 Jul 7-12; Vancouver, 121
66. Wolf RF, Ng B, Weksler B, et al. Effect of growth hormone on tumor and host in an animal model. Ann Surg Oncol 1994; 4: 314-20
67. Hirschfeld S, Tudor-Williams G, Zafonte M, et al. HIV infected children with growth failure respond to exogenous growth hormone or IGF-I [abstract]. International Congress of Endocrinology; 1996 Jun 12-15; San Francisco
68. Hirschfeld S, Tudor-Williams G, Stocker V, et al. Effects of recombinant human growth hormone and recombinant insulin-like growth factor-I administration in children with human immunodeficiency virus infection and growth failure [abstract]. 2nd International Conference on Retroviruses and Opportunistic Infections; 1995 Jan; Washington, DC
69. Goulet O, Pinto G, Brauner R, et al. Recombinant human growth hormone therapy for cachexia in HIV-infected children [abstract]. Second International Conference on Nutrition and HIV infection. 1997 Apr 23-25; Cannes
70. Beal JA, Martin BM, Ballen K. The clinical management of wasting and malnutrition in HIV/AIDS. AIDS Patient Care 1995; 9 (2): 66-74
71. Hellerstein MK. Pathophysiology of lean body wasting and nutrient unresponsiveness in HIV/AIDS: therapeutic implications. Nutrition and HIV/AIDS 1992 (1): 17-25
72. Turner J, Muurahainen N, Terrell C, et al. Nutritional status and quality of life [abstract]. 10th International Conference on AIDS; 1994 Aug 7-12; Yokohama, 35
73. Ott M, Fischer H, Polat H, et al. Bioelectrical impedance analysis as a predictor of survival in patients with human immunodeficiency virus infection. J Acquir Immune Defic Syndrom Hum Retrovirol 1995; 1995 (9): 20-5
74. Guenter P, Muurahainen N, Simons G, et al. Relationships among nutritional status, disease progression, and survival in HIV infection. J Acquir Immune Defic Syndr 1993; 6: 1130-8
75. Grunfeld C, Kotler DP. Pathophysiology of the AIDS wasting syndrome. AIDS Clin Rev 1992: 191-224
76. Mulligan K, Tai VW, Greenblatt R, et al. Body composition and resting energy expenditure in women with HIV infection [abstract], 11th International Conference on AIDS. 1996 Jul 7-12; Vancouver, 122
77. Oster MH, Enders SR, Samuels SJ, et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med 1994 Sep 15: 121: 400-8
78. Tchekmedyian NS, Hickman M, Heber D. Treatment of anorexia and weight loss with megestrol acetate in patients with cancer or acquired immunodeficiency syndrome. Semin Oncol 1991 Feb; 18 Suppl. 2: 35-42
79. Von Roenn JH, Armstrong D, Kotler DP, et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994 Sep 15; 121: 393-9
80. Von Roenn JH. Randomized trials of megestrol acetate for AIDS-associated anorexia and cachcxia. Oncology 1994 Oct; 51 Suppl. 1: 19-24
81. Sanchez-Colombo J, Diaz-Linares M, Novak R. The effects of high-dose megestrol acetate in women with AIDS related cachexia [abstract]. Pharmacotherapy 1996 May-Jun; 16: 502
82. Beal JE, Olsone R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10 (2): 89-97
83. Waters D, Danska J, Hardy K, et al. Recomhinant human growth hormone, insulin-like growth factor 1. and combination therapy in AIDS-associated wasting: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996 Dec 1; 125: 865-72
84. + counts disease stages based on treatment protocols. J Acquir Immune Defic Syndrom Hum Retrovirol 1996; 12 (4): 413-20